Core Viewpoint - The company JinKai Life Science has shown a decline in stock price and trading volume, while its business focuses on providing CDMO services for pharmaceutical companies, particularly in the areas of small molecule drug intermediates and fluorinated chemicals [1][5]. Group 1: Company Overview - JinKai Life Science specializes in providing custom development and manufacturing services for small molecule drug intermediates and a limited amount of active pharmaceutical ingredients to global pharmaceutical companies [2][8]. - The company’s main products include fluorinated and non-fluorinated CDMO services, with a significant focus on the production of intermediates for drugs like Semaglutide [2][3]. - As of November 28, the company had 14,500 shareholders, a decrease of 2.89% from the previous period, with an average of 3,902 circulating shares per shareholder, an increase of 2.98% [8]. Group 2: Financial Performance - For the period from January to September 2025, JinKai Life Science achieved a revenue of 488 million yuan, representing a year-on-year growth of 25.96%, and a net profit attributable to shareholders of 103 million yuan, reflecting a significant increase of 163.24% [8]. - The company reported that overseas revenue accounted for 61.18% of total revenue, benefiting from the depreciation of the Chinese yuan [4]. Group 3: Market Activity - On December 4, the stock price of JinKai Life Science fell by 0.75%, with a trading volume of 32.49 million yuan and a turnover rate of 1.72%, leading to a total market capitalization of 3.99 billion yuan [1]. - The main capital inflow for the day was negative at 3.47 million yuan, indicating a reduction in main capital over three consecutive days [5][6].
金凯生科跌0.75%，成交额3249.27万元，近3日主力净流入-1246.99万